SCNI

Scinai Immunotherapeutics Ltd. (SCNI) Porter's 5 Forces Analysis (2026)

Invetso Score: 5.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Competitive Rivalry

Score: 5.6 (Moderate)

SCNI appears to compete in a fragmented, price-sensitive niche where peers can win share on service and local relationships, limiting industry-wide margin expansion.

Rivalry is moderated if SCNI serves specialized end-markets with switching frictions, but global peers with broader scale can still pressure pricing in contested accounts.

Because the company lacks clear evidence of category dominance versus larger peers, competitive intensity likely constrains realized pricing power more than for top-tier incumbents.

Threat Of New Entrants

Score:

Entry barriers are likely moderate where customer qualification, regulatory compliance, or distribution access matter, but these protections do not fully exclude well-capitalized entrants.

Compared with global peers, SCNI may benefit from local incumbency and customer familiarity, yet those advantages are usually weaker than scale-based barriers in concentrated industries.

New entrants can still target narrower segments with digital channels or outsourced production, which keeps long-run pricing discipline tighter than in highly protected markets.

Bargaining Power Of Suppliers

Score:

Supplier power is likely meaningful if SCNI relies on a limited set of inputs or contract manufacturers, creating margin sensitivity versus larger peers with better sourcing leverage.

Global peers typically secure better terms through scale, dual sourcing, and procurement concentration, so SCNI may face relatively higher input-cost pass-through risk.

Where inputs are commoditized, supplier leverage should be limited, but any specialized components or logistics dependencies can still compress gross margin in weaker cycles.

Bargaining Power Of Buyers

Score:

Buyer power appears elevated if SCNI sells into concentrated channels or enterprise accounts, where customers can compare alternatives and negotiate on price and service.

Relative to global peers, smaller scale usually reduces SCNI’s ability to resist discounting, especially when buyers can multi-source or delay purchases.

If end-demand is discretionary, customers can shift volume to lower-priced peers, which keeps realized pricing and mix less resilient across the cycle.

Threat Of Substitutes

Score:

Substitution risk is moderate where customers can switch to alternative materials, outsourced services, or in-house solutions that cap pricing upside across the industry.

Global peers with differentiated offerings usually defend share better, while SCNI may have less ability to offset substitution through brand or ecosystem lock-in.

The threat becomes more binding in commoditized applications, where functional equivalence makes price the main decision variable and compresses margins.

Overall Score

Score:

SCNI’s industry structure appears to leave it with limited pricing power versus global peers, as moderate buyer and supplier pressure likely outweighs only partial barriers to entry and substitution.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Scinai Immunotherapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →